Australia-based ResApp, a public company, has raised $9.74 million ($12.5 million Australian dollars) for its product, a smartphone-based system for diagnosing respiratory conditions. The company sold 62.5 million new ordinary shares at $0.16 ($0.20 AU) per share.
ResApp’s offering essentially uses the smartphone microphone as a stethoscope to listen to a patient’s breathing. But instead of...
